Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4803187 | 0.87 | BRD4 (0.44) | DRD4BRD4MAPK11MAPK14 | |
| SCHEMBL4254230 | 0.85 | BRD4 (0.41) | DRD4BRD4MAPK11MAPK14 | |
| SCHEMBL17883348 | 0.85 | HDAC8 (0.45) | HDAC1HDAC6HDAC8HDAC2HDAC10 | |
| SCHEMBL1608560 | 0.78 | MEN1 (0.57) | HDAC1HDAC6HDAC8HDAC4HDAC2 | |
| SCHEMBL1607723 | 0.75 | HDAC6 (0.41) | HDAC1HDAC6HDAC8HDAC4HDAC2 | |
| SCHEMBL2611215 | 0.73 | HDAC1 (0.44) | HDAC1HDAC6HDAC8HDAC4HDAC2 | |
| SCHEMBL18003159 | 0.73 | CYP2A6 (0.53) | BRD4 | |
| SCHEMBL31636989 | 0.72 | MAPK11 (0.56) | HDAC1HDAC6HDAC8HDAC4HDAC2 | |
| SCHEMBL1608595 | 0.72 | HDAC6 (0.46) | HDAC1HDAC6HDAC8HDAC4HDAC2 | |
| SCHEMBL1607720 | 0.72 | HDAC6 (0.48) | HDAC1HDAC6HDAC8HDAC4HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371281-B2 | Indole derivatives as inhibitors of histone deacetylase | PHARMACYCLICS LLC (US) | 2016-06-21 | — | — | US | claimed |
| US-20150299119-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS LLC | 2015-10-22 | — | — | US | claimed |
| US-20150038542-A1 | USES OF SELECTIVE INHIBITORS OF HDAC8 AND TREATMENT OF INFLAMMATORY CONDITIONS | PHARMACYCLICS LLC | 2015-02-05 | — | — | US | claimed |
| US-20130078215-A1 | USES OF SELECTIVE INHIBITORS OF HDAC8 FOR TREATMENT OF INFLAMMATORY CONDITIONS | PHARMACYCLICS, INC. (US) | 2013-03-28 | — | — | US | claimed |
| US-20110150825-A1 | USES OF SELECTIVE INHIBITORS OF HDAC8 FOR TREATMENT OF INFLAMMATORY CONDITIONS | PHARMACYCLICS, INC. (US) | 2011-06-23 | — | — | US | claimed |
| US-20070281934-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2007-12-06 | — | — | US | claimed |
| US-9371281-B2 | Indole derivatives as inhibitors of histone deacetylase | PHARMACYCLICS LLC (US) | 2016-06-21 | — | — | US | disclosed |
| US-20150299119-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS LLC | 2015-10-22 | — | — | US | disclosed |
| US-20150038542-A1 | USES OF SELECTIVE INHIBITORS OF HDAC8 AND TREATMENT OF INFLAMMATORY CONDITIONS | PHARMACYCLICS LLC | 2015-02-05 | — | — | US | disclosed |
| US-8900565-B2 | Indole derivatives as inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20130156727-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130078215-A1 | USES OF SELECTIVE INHIBITORS OF HDAC8 FOR TREATMENT OF INFLAMMATORY CONDITIONS | PHARMACYCLICS, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8338416-B2 | Indole derivatives as inhibitors of histone deacetylase | PHARMACYLICS, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110150825-A1 | USES OF SELECTIVE INHIBITORS OF HDAC8 FOR TREATMENT OF INFLAMMATORY CONDITIONS | PHARMACYCLICS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-7820711-B2 | Uses of selective inhibitors of HDAC8 for treatment of T-cell proliferative disorders | PHARMACYCLICS INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20090203010-A1 | MSMB-gene based diagnosis, staging and prognosis of prostate cancer | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2009-08-13 | — | — | US | disclosed |
| WO-2009089598-A2 | MSMB-GENE METHYLATION BASED DIAGNOSIS, STAGING AND PROGNOSIS OF PROSTATE CANCER | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2009-07-23 | — | — | WO | disclosed |
| WO-2008060721-A1 | USES OF SELECTIVE INHIBITORS OF HDAC8 FOR TREATMENT OF T-CELL PROLIFERATIVE DISORDERS | PHARMACYCLICS, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080112889-A1 | Uses of Selective Inhibitors of HDAC8 for Treatment of T-Cell Proliferative Disorders | PHARMACYCLICS, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20070281934-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299119-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | HDAC8, HDAC1, HDAC2 | HDAC1 2/4885HDAC6 10/4885HDAC8 1/4885 |
| US-20080112889-A1 | Uses of Selective Inhibitors of HDAC8 for Treatment of T-Cell Proliferative Disorders | HDAC8, HDAC5, HDAC7 | HDAC1 4/4885HDAC6 12/4885HDAC8 1/4885 |
| US-20110150825-A1 | USES OF SELECTIVE INHIBITORS OF HDAC8 FOR TREATMENT OF INFLAMMATORY CONDITIONS | HDAC8, HDAC2, HDAC7 | HDAC1 5/4885HDAC6 9/4885HDAC8 1/4885 |
| US-20070281934-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | HDAC8, HDAC1, HDAC2 | HDAC1 2/4885HDAC6 10/4885HDAC8 1/4885 |
| US-20130078215-A1 | USES OF SELECTIVE INHIBITORS OF HDAC8 FOR TREATMENT OF INFLAMMATORY CONDITIONS | HDAC8, HDAC2, HDAC7 | HDAC1 5/4885HDAC6 9/4885HDAC8 1/4885 |
| US-20090203010-A1 | MSMB-gene based diagnosis, staging and prognosis of prostate cancer | MAT2B, DNMT3B, SHBG | HDAC1 3460/4885HDAC6 4661/4885HDAC8 2668/4885 |
| US-20150038542-A1 | USES OF SELECTIVE INHIBITORS OF HDAC8 AND TREATMENT OF INFLAMMATORY CONDITIONS | HDAC8, HDAC2, HDAC7 | HDAC1 5/4885HDAC6 9/4885HDAC8 1/4885 |
| US-20130156727-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | HDAC8, HDAC1, HDAC2 | HDAC1 2/4885HDAC6 10/4885HDAC8 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.